Clinical trials: Hepatitis C Virus (HCV)
Human Immunodeficiency Virus, Hepatitis C
Impact of Hepatitis C Therapy and Bone Health
An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.
- Trial name
- HCV (NCT03221582)
- Testing
- EBR/GZR
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Dallas VA Medical Center
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
This equally randomized (1:1), double-blind, parallel arm study will assess the safety and antiviral efficacy of RO5024048 added to standard Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) therapy in patients with…
- Trial name
- NCT01057667
- Testing
- RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]
- Where
- 25 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1
This is a randomized, open-label, parallel group, multicenter pilot study evaluating the efficacy and safety of alternative dosing of ribavirin vs.
- Trial name
- RibaC (NCT01226771)
- Testing
- Ribavirin "loading" dose given, "Priming" dose of ribavirin given, Group C ("Standard-of-Care")
- Where
- Sweden
- Volunteers
- 105 people
- Sponsor
- Göteborg University
Hepatitis C, Chronic
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C.
- Trial name
- NCT01679834
- Where
- 2 sites in Germany
- Volunteers
- 7,500 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Substance Abuse Treatment Centers
Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine.
- Conditions
- Hepatitis C, Chronic, Substance Abuse Treatment Centers, Opioid-Related Disorders
- Trial name
- HepCOP (NCT00473993)
- Sponsor
- Seidenberg, Arztpraxis A., M.D.
Hepatitis C Virus (HCV)
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.
- Trial name
- NCT03341871
- Where
- Japan
- Volunteers
- 1,095 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
This Phase 3 clinical study is designed to evaluate the safety, tolerability, and efficacy of two dose levels of Infergen (interferon alfacon-1, CIFN) plus Ribavirin administered daily for 48 weeks and no treatment in patients…
- Trial name
- NCT00162734
- Testing
- Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
- Volunteers
- 144 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis C
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
The primary purpose of the study is to compare the safety and effectiveness of standard treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) to those same medications plus a dietary…
- Trial name
- NCT00571714
- Testing
- Peginterferon alpha-2a and ribavirin, Peginterferon alpha-2a , ribavirin and betaine
- Sponsor
- University of Nebraska
Hepatitis C
Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1)
This is a Phase 4, descriptive, observational, open, prospective study of patients who their doctor prescribes INFERGEN for clinical practice. No medication was provided by the sponsor.
- Trial name
- OBSERVER (NCT01426204)
- Volunteers
- 40 people
- Sponsor
- Closter Pharma
Chronic Hepatitis C
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
This study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2 or 3 chronic hepatitis
- Trial name
- NCT00759200
- Testing
- alb-interferon alfa 2b, peg-interferon
- Where
- 55 sites in Australia, Canada and 10 more
- Volunteers
- 525 people
- Sponsor
- Novartis
Chronic Hepatitis C
Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C
The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian…
- Trial name
- ViZIR (NCT02099604)
- Testing
- Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
- Where
- Egypt
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with…
- Trial name
- NCT05854511
- Testing
- Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
Hepatitis C, Acute, Diabetes
HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt
An observational double-blind cohort study that examined the association between HCV viral hepatitis, blood sugar level and systolic blood pressure in the Egyptian population
- Conditions
- Hepatitis C, Acute, Diabetes, Hypertension
- Trial name
- NCT03839979
- Testing
- BIOLINE HCV kits, ACCU-CHEK kits, ErKameter 3000 mercury manometer
- Where
- Egypt
- Volunteers
- 71,975 people, healthy volunteers welcome
- Sponsor
- Cairo University
Cirrhosis, Chronic Hepatitis C
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy…
- Trial name
- NCT00502086
- Testing
- Viusid (nutritional supplement)
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Hepatitis C, Chronic
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)
The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination…
- Trial name
- NCT00081770
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), REBETOL (ribavirin; SCH 18908), PEGASYS (peginterferon alfa-2a)
- Volunteers
- 4,469 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
A phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the combined single dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir \& Ribavirin) versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a…
- Trial name
- NCT03186313
- Testing
- Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Egyptian Liver Hospital
Hepatitis B, Hepatitis C
Chronic Hepatitis B and C Recall Northern Holland
The project aims to retrieve patients diagnosed with chronic hepatitis B (cHB) and hepatitis C (cHC) who are lost to follow-up.Data files of the Public Health System and microbiology laboratories will be explored for registered…
- Trial name
- NCT02687061
- Volunteers
- 300 people
- Sponsor
- Stichting MDL Holland-Noord
Chronic Hepatitis C
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
Introduction: Vitamin D binding protein (VDBP) is a potential modulator of immune response and is associated with clinical progression of many diseases.
- Trial name
- NCT02788682
- Testing
- WT+ Diplotype
- Volunteers
- 162 people
- Sponsor
- Cairo University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.